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A Ab bs st tr ra ac ct t
Alzheimer’s disease is a progressive neurodegenerative disorder with high prevalence in old age.
It is the most common cause of dementia, with a risk reaching 50% after the age of 85 years, and
with the increasing age of the population it is one of the biggest healthcare challenges of the 21st
century. Genetic variation is an important contributor to the risk for this disease, underlying an
estimated heritability of about 70%. Alzheimer’s genetics research in the 1990s was successful in
identifying three genes accounting for most cases of early-onset disease with autosomal dominant
inheritance, and one gene involved in the more common late-onset disease, which shows
complex inheritance patterns. Despite the presence of significant remaining genetic contribution
to the risk, the identification of genes since then has been elusive, reminiscent of most other
complex disorders. In the past decade there have been significant efforts towards a systematic
evaluation of the multiple genetic association studies for Alzheimer’s disease, while the first
genome-wide association studies are now being reported with promising results. As sample sizes
grow through new collections and collaborative efforts, and as new technologies make it possible
to test alternative hypotheses, it is expected that new genes involved in the disease will soon be
identified and confirmed. The gene discoveries of the 1990s have taught us a lot about Alzheimer’s
disease pathogenesis, providing many therapeutic targets that are currently at various stages of
testing for future clinical use. As new genes become known and the biological pathways leading to
disease are further explored, the possibility of prevention and successful personalized treatment
is becoming tangible, providing hope for the millions of patients with Alzheimer’s disease and
their caregivers.
Published: 27 March 2009
Genome Medicine 2009, 1 1: :34 (doi:10.1186/gm34)
The electronic version of this article is the complete one and can be
found online at http://genomemedicine.com/content/1/3/34
© 2009 BioMed Central Ltd 
I In nt tr ro od du uc ct ti io on n: :   A Al lz zh he ei im me er r’ ’s s   g ge en ne et ti ic cs s   i in n   t th he e   2 20 0t th h   c ce en nt tu ur ry y
Alzheimer’s disease (AD), first described by Alois
Alzheimer in 1907 [1], is a neurodegenerative disorder
progressing from memory loss to profound dementia and
death within an average of eight years. Although clinical
diagnosis is reliable in more than 90% of cases, the definite
diagnosis is assigned post mortem based on brain atrophy
and the characteristic neuropathologic findings, which
involve intracellular neurofibrillary tangles containing
hyperphosphorylated tau protein and extracellular amyloid
plaques containing deposits of beta amyloid (Aβ). AD is
recognized today as the most common cause of dementia in
the elderly.
In the 1930s a number of reports described familial cases of
AD with multiple affected individuals in each generation,
consistent with an autosomal dominant mode of inheritance
[2-4]. Like Alzheimer’s first patient, the age of onset of the
familial cases was most often below 65 years, which led
physicians to identify AD as pre-senile dementia, distingui-
shing it from senile dementia. By 1980, however, it had
become evident that the two types of dementia are essen-
tially identical, named by Terry and Davies [5] as dementia
of the Alzheimer type.
Not surprisingly, the genes involved in the familial, auto-
somal dominant AD (FAD) were quickly discovered duringthe golden years of gene mapping in the 1990s. Despite
initial confusion and controversy due to the genetic hetero-
geneity of AD [6,7], extending even to the small subset of
FAD, a combination of functional evidence, linkage analyses
and sequence comparisons led to the identification of the
three genes accounting for most FAD cases: APP [8], PSEN1
[9] and PSEN2 [10].
The majority (95%) of AD cases, however, are of later onset
and do not follow Mendelian inheritance, despite showing
significant heritability [11,12]. Like most other psychiatric
disorders, the genetics of the late-onset disease appear to be
complex. AD is the first complex disorder for which a gene
was identified through an association with a DNA variant, a
variant in the APOE gene whose effect has been consistently
observed since. Apolipoprotein E was known to have three
common isoforms, ε2, ε3 and ε4, that are determined by two
coding single nucleotide polymorphisms (SNPs). After
observing high-avidity binding of Aβ to APOE, and en-
couraged by previous linkage reports around the APOE locus
on chromosome 19, Strittmatter et al. [13] examined the
three isoforms in cases and controls and found a significant
excess of ε4 in the cases. Today, after many follow-up
studies, it has been determined in populations of European
descent that ε3ε4 heterozygotes have a two- to three-fold
higher risk of developing AD compared to ε3ε3 homo-
zygotes. The increase in risk for ε4ε4 homozygotes is more
than twice that of the ε3ε4 heterozygotes, while ε2 hetero-
zygotes have a reduced risk.
The significance of the identification of APOE as a risk factor
for AD stretched beyond the obvious importance for AD
research. It was a proof of principle for the ‘common disease -
common variant’ hypothesis that was at the time becoming
increasingly popular. This result encouraged investigators to
perform many candidate gene association studies for AD and
other disorders; unfortunately, most did not enjoy the same
degree of consistent replication.
A Al lz zh he ei im me er r’ ’s s   g ge en ne et ti ic cs s: :   r re ec ce en nt t   p pr ro og gr re es ss s
Since the discovery of an association of APOE with AD in
1993, there have been numerous publications of genetic
association studies reporting mixed results and plagued by
the lack of consistent replications. Initially, most studies
examined one polymorphism per gene, often without evi-
dence that the polymorphism had any functional signifi-
cance. At that time (in the mid- to late nineties) this was
considered acceptable practice because little genetic
variation was known and dbSNP, the database of DNA poly-
morphisms [14], did not become available until 1998. It later
became clear that a more dense survey of variation in and
around a gene was necessary to be confident that it has been
adequately tested for association. It also became clear that it
is not necessary to genotype all SNPs in a gene because, as a
result of linkage disequilibrium (LD), the number of haplo-
types observed in the population is lower than the possible
combinations of alleles [15]. As the International HapMap
Project [16] started to make data available for characterizing
LD, investigators started performing more comprehensive
association analyses, genotyping enough SNPs to capture
and investigate all known common variations in each gene.
This, however, came with the price of increased multiple
comparisons, further complicating the interpretation of
results. Power was reduced due to statistical corrections,
while the significance of studies that identified associations
for the same gene but for different SNPs was hard to
interpret. In an effort to put order into these results,
Bertram  et al. [17] catalogued all published association
studies for AD, in a public database called AlzGene [18]. In
December 2005 the AlzGene database contained 802 differ-
ent polymorphisms in 277 genes, while meta-analyses
pointed to a little over a dozen of these genes as the most
reliable associations [17]. By January 2009 the contents of
the database had doubled to 557 genes and 1,852 poly-
morphisms. This large assembly of studies is a useful tool for
AD genetics investigators around the world and it has
become increasingly valuable as it incorporates more recent
results from genome-wide association studies (GWAS).
However, it is important to remember the inherent biases of
candidate gene studies, which comprise the majority of the
AlzGene database entries. Most of the reported genes were
chosen because of their known functions, linkage evidence
or both. In addition, it is impossible to estimate publication
bias and this is itself influenced by prior linkage and
functional evidence. Thus, inferences about biological path-
ways or further support of linkage regions based on most of
these data should be avoided, with the exception perhaps of
results from GWAS.
Linkage studies on late-onset AD have suffered similar
limitations to those observed in association studies. Multiple
genome-wide studies have been performed, often including
overlapping samples, yet they have not been consistent in
the genomic regions they identify and they rarely replicate
each other’s results. Only a few genomic regions including
chromosomes 9, 10 and 12 have been more consistently
identified by linkage [19]; however, the presence of risk
alleles within these regions remains unproven. The success
of GWAS has led investigators today to pay less attention to
linkage in complex disorder, leading to a current lack of new
linkage results. It must be noted that under allelic hetero-
geneity, linkage would be successful where association tests
would fail to give a positive result. In view of FAD being
caused by more than 150 different mutations in the PSEN1
gene, it should be no surprise if the risk for late-onset AD is
increased by more than ten different variants in a gene.
Today it is sensible to follow the GWAS approach to find the
first risk genes after APOE, because laboratory and analy-
tical methods for identifying multiple rare disease-causing
alleles across many genes are still in their infancy. New and
emerging analytical methods and second-generation sequen-
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hypothesis in projects that will probably be guided by prior
linkage and GWAS findings.
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Through January 2009 there have been four reports of
GWAS for AD that analyzed individual genotypes, and a
report of a study that genotyped pooled samples. An addi-
tional study has used a pooling strategy to investigate
potentially functional SNPs across the genome. Not sur-
prisingly, all studies identified the APOE association,
proving the power of the approach under the ‘common
disease - common variant’ hypothesis. None of these studies
exceeded a sample size of 2,500 (cases and controls) and
they can therefore be considered of modest size for the
purpose of a GWAS. The studies have shown no overlap in
terms of the identified loci other than APOE, and most
findings have yet to be replicated by independent groups.
Nevertheless, they have each reported interesting results.
The study by Grupe et al. [20] in April 2007 used a pooling
strategy and multiple follow-up sample sets to examine
more than 17,000 gene-based putative functional SNPs
across the genome. Although only SNPs around APOE
reached study-wide significance, many others provided
weaker evidence of association, overlapping significantly
with known linkage regions.
In the same month, Coon et al. [21] reported results on half a
million SNPs across the genome genotyped using the
Affymetrix platform on over 1,000 histopathologically verified
AD cases and controls. The main conclusion of that report
was that APOE is the only major susceptibility gene, yet in a
follow-up paper, Reiman et al. [22] stratified the cases by
APOE genotype and detected a strong association with SNPs
in the GAB2 gene, altered GAB2 transcript levels in
vulnerable neurons, and an effect of GAB2 levels on tau
phosphorylation. The association has since been tested in
other samples, and although the results are conflicting [23-
26], the occurrence of more than one independent replica-
tion [24,26] of an association that originated from an un-
biased GWAS is encouraging.
In September 2008, Abraham et al. [27] reported on a study
of over 1,000 pooled cases and 1,200 pooled controls
genotyped on approximately 550,000 SNPs on the Illumina
platform. The authors observed only one strong signal over
the APOE gene. Follow-up of weaker signals by individual
genotyping identified the LRAT gene, whose product plays a
prominent role in the vitamin A cascade, as another
potential association with AD.
In November 2008, Bertram et al. [28] reported on a GWAS
analyzing 500,000 SNPs in a sample of 410 families and
using multiple other samples for replications. Using family-
based tests and incorporating age of onset information, they
identified a SNP on chromosome 14q31 that, like the APOE
variants, appears to be a modifier of age of onset, while other
SNPs with weaker signals were also reported. No annotated
gene was found in that genomic region in the University of
California Santa Cruz (UCSC) database, with the exception
of a computationally predicted gene and three expressed
sequence tags (ESTs). This study also found some support
for the GAB2 gene and one of the SNPs reported by the
Grupe et al. study [20], while failing to support many other
previous associations.
In January 2009, Beecham et al. [29] reported a GWAS on
the Illumina platform analyzing approximately 550,000
SNPs in nearly 500 AD cases and 500 controls. Other than
APOE, the study identified a SNP on chromosome 12q13 that
met their criterion for genome-wide significance, a false-
discovery rate of less than 0.20. This association was
replicated in an independent sample, and it lies in a genomic
region that has been previously reported to show significant
genetic linkage to the disease [30-33]. Perhaps most
interestingly, the authors reported that out of the 19 best
distinct signals, 12 were found in regions with prior linkage
evidence, consistent with the expectation of enrichment for
true signals [34].
Carrasquillo et al. [35] have recently published a GWAS for
AD on 844 cases and 1,255 controls, using an Illumina
platform to assay approximately 314,000 SNPs. Although in
their stage 1 analysis only APOE SNPs reached genome-wide
significance, a signal on chromosome X provided strong
evidence in the replication samples, giving a combined P-
value as low as 3.9 × 10-12. This signal was within the
PCDH11X gene, which encodes a protocadherin, a cell-cell
adhesion molecule expressed in the brain.
It is still too early to draw definite conclusions from the
results of the reported GWAS for AD. The sample sizes
analyzed are considerably smaller than those of GWAS that
have successfully identified genes for other complex dis-
orders [36]. For example, a large GWAS of seven major
diseases involving approximately 2,000 cases of each
disease and approximately 3,000 controls successfully iden-
tified associations for five disorders but showed much
weaker results for bipolar affective disorder and hyper-
tension [37], indicating that this sample size is adequate for
some but not all complex diseases. Some of the reported
associations for AD will probably point to new genes as more
investigators replicate them and further analyze the variants
functionally; however, it appears that the GWAS on AD
might still be underpowered and the effect sizes of the
remaining AD-associated variants are as small as those seen
in other GWAS. In other words, it becomes more and more
clear that APOE is the exception rather than the rule,
making AD an interesting case of a complex disorder that
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extensive allelic heterogeneity, one gene with common allelic
variation and a considerable effect on the risk and the age of
onset, and multiple other variants with seemingly smaller
effects. With a few genes already in hand, with the first
GWAS opening the way for more to follow, and with new
sequencing technologies emerging and promising to test the
possibility of multiple rare variants, these are exciting times
for AD genetics research.
C Co on nt tr ri ib bu ut ti io on n   o of f   A AD D   g ge en ne et ti ic cs s   t to o   t tr re ea at tm me en nt t   a an nd d
d di ia ag gn no os si is s
It is now more than 15 years since the discovery of the first
genes involved in AD, and while we are still on a quest for
additional genes, we have learned a lot about the disease.
The processing of APP through cleavage by γ-secretase, an
enzymatic complex whose catalytic subunit is formed by the
presenilins [38], is considered by many as a key in the
disease process. It leads to generation of the amyloidogenic
peptide Aβ (Figure 1) and its aggregation into fibrils and
toxic oligomeric forms, the earliest effectors of synaptic com-
promise [39], followed by neurodegeneration. The direct
involvement of the products of at least three out of the four
known genes in this hypothesis is no coincidence and
significantly strengthens the confidence that this is a
promising target for treatment. These genes have greatly
enhanced our knowledge of the pathway leading to the
production of amyloid (Figure 1), which has in turn provided
targets for intervention.
Treatments targeting APP processing include those diverting
cleavage toward the non-amyloidogenic α-secretase pathway
(α-secretase enhancers) and those inhibiting the amyloido-
genic pathway of beta and gamma secretase (β- or γ-
secretase inhibitors). Pharmacological agents that enhance
α-secretase activity include, among others, non-steroidal
anti-inflammatory drugs (NSAIDs), statins and estrogens
through activation of protein kinase C [40]. These agents
have been tested with varying results. The effectiveness of
estrogens has been suggested by many in vitro and in vivo
studies; however, data from the Women’s Health Initiative
Memory Study [41], a large randomized controlled trial, did
not show a consistent positive effect. The possibility that
there is a critical period for neuroprotection [42] and that
genetic variation or other predisposing factors might modify
the effects of estrogens requires further examination [43].
The use of NSAIDs has seen support from epidemiological
studies as likely to reduce the risk for the disease; however,
the results of clinical investigations so far have not been
encouraging [44,45]. The use of statins for AD prevention
has shown conflicting results. Initial cross-sectional studies
showed risk reductions that were better than 50% (for a
review see Rockwood et al [46]). Clinical trials and cohort
studies, however, failed to show the protective effect that has
been consistently observed in cross-sectional studies [46].
The possibility of indication bias in cross-sectional studies
(that is, people with AD are less likely to receive statin
treatment) cannot be ruled out, although it has been
accounted for by some studies [46]. The debate and interest
in statins remains open, as support from prospective clinical
trials is clearly necessary before they can be considered a
preventive measure for AD [47]. The recognition that
ADAM10 from the ADAM family of metalloproteases
exhibits α-secretase activity [48] and is regulated by retinoic
acid [49] has led to the inclusion of retinoic acid in the list of
potential therapeutic agents [50]. Retinoic acid has shown
promising results in an AD mouse model [51] but its
potential as a therapeutic agent for AD in humans has not
yet been examined.
Agents that inhibit the amyloidogenic pathway include β-
and  γ-secretase inhibitors. Beta-secretase inhibitors have
only recently been developed [52], and initial tests on
transgenic mice are positive, showing decreased Aβ produc-
tion [53]. Gamma-secretase inhibitors have also shown
positive results in laboratory animal models and, adminis-
tered in low doses, they are safe in humans and reduce
plasma Aβ [54]. A major limitation in the use of these inhibi-
tors is that APP is not the only substrate of γ-secretase. Other
substrates include NOTCH, ERBB4 and many other type I
membrane protein stubs [54]; therefore, significant inhibi-
tion of the enzyme could lead to serious side-effects. This
limitation might be bypassed to some extent as more
selective agents are developed.
The role of APOE in AD appears to be more complex than
that of APP and the presenilins. Studies of its functional
involvement have implicated the homeostasis of cholesterol
and phospholipids, synaptic integrity, amyloid metabolism,
phosphorylation of tau, accumulation of neurofibrillary
tangles and neuronal survival [55]. Nevertheless, APOE is an
important player in pharmacological intervention research.
Many studies have suggested that the APOE genotype can
influence the outcome of existing treatments [56], making it
interesting from a pharmacogenetics perspective, while
others have suggested that targeting the regulation of APOE
expression is a potential treatment approach [55,57].
Interestingly, drugs that modify the expression of APOE
include statins which, as discussed above, have already
shown promise.
Many of the genes that have been implicated in AD - albeit
not consistently - by association studies are involved in
multiple aspects of the disease [58], including the generation
of neurofibrillary tangles, amyloid aggregation, amyloid
clearance, oxidative stress and hypoxia, inflammation and
apoptotic cell death. Most of these processes are already
targeted by therapeutic agents either directly or through
effects of drugs chosen to target other disease mechanisms.
When the validity and exact nature of the genetic asso-
ciations is elucidated in the near future, together with new
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strategies to intervene will become clearer.
At the level of molecular genetic diagnosis and risk
assessment, there is a sharp divide between early- and late-
onset disease. In FAD, mutations in one of three genes (APP,
PSEN1 and  PSEN2) can be found in more than 80% of
patients [59]. Although there is currently no effective cure or
prevention strategy, knowledge of the risk, and prenatal
diagnosis, might be desired and is possible. For late-onset
AD, however, our current knowledge does not allow useful
genetic testing. The increase in risk by APOE ε4 is of
questionable use as most carriers will not become affected
and half of the patients do not carry this allele. This is even
more questionable for less established genetic associations.
As we begin to discover more and more genes and genetic
variants involved in AD and learn the details of their
functions and interactions with each other and the environ-
ment, it is most likely that one day in the not so distant
future accurate risk and age of onset prediction will become
a reality. Such capability, combined with strategies for
prevention and effective treatments, perhaps tailored to each
patient through pharmacogenetics, could lead to solving this
major public health problem.
C Co on nc cl lu us si io on ns s
Initial successes in relation to the genetics of AD were
followed by frustration as investigators addressed the more
common and genetically complex late-onset disease. The
four AD genes identified in the 1990s provided important
knowledge on the disease pathogenesis at the molecular
level. While no new gene has been positively identified since
then, there is a wealth of new data from potentially impor-
tant genetic linkage and association studies. As powerful
tools for high-throughput DNA analysis are becoming
available, the first GWAS are emerging, and extensive DNA
sequencing studies will probably follow. Those will soon lead
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F Fi ig gu ur re e   1 1
The amyloidogenic and non-amyloidogenic cleavage pathway of APP. Mutations in APP, PSEN1 or PSEN2 cause early-onset AD. PSEN1 and 2 are
components of γ-secretase. The amyloidogenic peptide Aβ is shown in orange.
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Aβto further breakthroughs, improving our understanding of
genetic risk, and allowing better gene-based approaches to
prevention and treatment.
A Ab bb br re ev vi ia at ti io on ns s
Aβ, amyloid beta; AD, Alzheimer’s disease; EST, expressed
sequence tag; FAD, familial Alzheimer’s disease; GWAS,
genome-wide association studies; LD, linkage disequili-
brium; NSAID, non-steroidal anti-inflammatory drug; SNP;
single nucleotide polymorphism; UCSC, University of
California Santa Cruz.
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